Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Pacira BioSciences (Nasdaq: PCRX) granted inducement equity awards on May 4, 2026 to ten new employees under its Amended and Restated 2014 Inducement Plan as permitted by Nasdaq Listing Rule 5635(c)(4).
The Committee approved options for an aggregate of 36,800 shares and restricted stock units for 27,700 shares. Options carry a 10-year term, four-year vesting; RSUs vest annually over four years beginning May 4, 2027, and awards use a $24.69 exercise price for options.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peer moves are mixed: AMPH appeared in momentum scanners down 18.10% while BGM was up 6.85%. PCRX’s pre-news move of -0.21% and near-average volume suggest this announcement was stock-specific and not part of a coordinated sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 05 | Stockholder letter | Neutral | -4.4% | Mailing of letter to stockholders ahead of upcoming annual meeting. |
| Apr 30 | Earnings results | Positive | -4.1% | Q1 2026 revenue growth, non-opioid portfolio update, and reiterated guidance. |
| Apr 28 | Proxy materials | Positive | -1.1% | Definitive proxy filing and shareholder letter highlighting strategy and milestones. |
| Apr 27 | Clinical real-world data | Positive | +4.2% | Real-world EXPAREL data showing reduced opioid use and medical costs. |
| Apr 16 | Earnings date notice | Neutral | +1.8% | Announcement of date and time for Q1 2026 earnings release and call. |
Recent communications and earnings-related releases often saw negative price reactions, while positive clinical/real‑world data produced a more favorable move.
Over the past month, Pacira has reported multiple developments. An April 16 earnings-date notice saw a modest 1.84% gain. Real‑world EXPAREL data on April 27 coincided with a stronger 4.24% rise. However, the April 30 Q1 2026 results and related 10‑Q/8‑K, despite revenue growth and reiterated guidance, were followed by declines of 4.12%. Subsequent proxy and stockholder letter communications on April 28 and May 5 also coincided with negative moves. Against this backdrop, today’s routine inducement grants fit into normal corporate activity rather than a major catalyst.
Market Pulse Summary
This announcement details routine inducement equity awards to new hires, including options on 36,800 shares and 27,700 RSUs at an exercise price of $24.69, vesting over four years. Such grants align with Nasdaq Listing Rule 5635(c)(4) and support talent recruitment. In context, PCRX was trading near its 200-day moving average and below its 52‑week high, with recent news-flow dominated by earnings, proxy materials, and clinical data. Investors may monitor how ongoing governance, compensation, and clinical milestones evolve from here.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
stock options financial
restricted stock units financial
AI-generated analysis. Not financial advice.
BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on May 4, 2026 to ten new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.
Three employees received stock options to purchase an aggregate of 36,800 shares of Pacira common stock and ten employees received restricted stock units for an aggregate of 27,700 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of
Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.
Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com Media Contact: Sara Marino, (973) 370-5430 sara.marino@pacira.com